Five main problems in the development of biomedicine in China

Introduction: Recently, Xu Ming, vice president of China Chamber of Commerce for the import and export of healthcare products, told the new drug exchange reporter at the pre conference preparatory meeting for the biopharmaceutical innovation and international technology transfer Summit: "the development of China's biopharmaceuticals is worrying, and the gap with developed countries is not only not narrowing, but also continuing to widen." Although the total sales revenue of biotechnological drugs in China has exceeded 100 billion yuan, the mainstream of biotechnological drugs in China is still at the level of imitation In the field of "intellectual property has the final say", the United States has about 59% of the power, the EU occupies 19% of the total, Japan occupies 17%, and the rest of the world share a total of only 5% As early as in 2009, when the general office of the State Council issued "several policies to accelerate the development of the biological industry", it established the strategic position of the biological pharmaceutical industry and put forward a more specific development strategy The industry ushered in a major opportunity period At the same time, biopharmaceutical industry has developed rapidly in the world, which has become an active field of drug research and development In the new drugs approved by FDA in recent two years, macromolecular drugs account for the vast majority In recent years, a number of biopharmaceutical companies have emerged in China, and the registration of biopharmaceutical products has also reached a climax Although there are many biomedical products in China, only a few have good market performance Currently, the products that are applying for registration are mainly biological analogues and imitations, and the real innovative products are rare Wu Chenbing, President of research and development of CITIC Guojian in Shanghai, believes that at this stage, there are three major problems in China's biopharmaceuticals: "the first is technology, the domestic biopharmaceuticals, especially in the field of antibody macromolecules, are basically imitated, and basic scientific research is scarce; the second is that policies and regulations fail to keep up with the development of this field, which requires more specific guidance in supervision; Thirdly, the lack of industrial capital is not the lack of money and investors in China, but the lack of investors with long-term vision and professional background " The report on the competitiveness of China's biomedical industry, compiled by China Chamber of health insurance, points out that at present, there are five major problems in the development of China's biomedical industry: first, the lack of R & D power, the lack of scientific and sound R & D system, and the large gap between R & D investment and developed countries; second, the lack of cutting-edge R & D, most of the products in the follow-up and imitation stage; Third, the ability of independent innovation is weak, and the conversion rate of scientific and technological achievements is low; fourth, there are few enterprises in the field, many small enterprises, and lack of competitiveness; fifth, the relevant system and mechanism are not perfect, and there is no scientific system in new drug registration and approval, investment and financing, product evaluation and pricing, market access, etc., which makes it difficult to achieve large-scale industrialization Wei Yuquan, academician of the Chinese Academy of Sciences, said that the research and development of biological drugs must focus on the transformation of achievements "Only with the active participation of enterprises, can scientific research have an industrial base, a more complete technology chain and an industrial chain be formed Product transformation can also drive enterprises to invest more "